Philip J. Vickers

5.3k total citations · 2 hit papers
36 papers, 3.8k citations indexed

About

Philip J. Vickers is a scholar working on Physiology, Molecular Biology and Genetics. According to data from OpenAlex, Philip J. Vickers has authored 36 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Physiology, 11 papers in Molecular Biology and 11 papers in Genetics. Recurrent topics in Philip J. Vickers's work include Asthma and respiratory diseases (15 papers), Estrogen and related hormone effects (11 papers) and Inflammatory mediators and NSAID effects (9 papers). Philip J. Vickers is often cited by papers focused on Asthma and respiratory diseases (15 papers), Estrogen and related hormone effects (11 papers) and Inflammatory mediators and NSAID effects (9 papers). Philip J. Vickers collaborates with scholars based in Canada, United States and Germany. Philip J. Vickers's co-authors include Jilly F. Evans, Joseph A. Mancini, Gary P. O’Neill, Stacia Kargman, John W. Gillard, S Jothy, Douglas K. Miller, Richard A. F. Dixon, S. Charleson and Ronald E. Diehl and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Philip J. Vickers

36 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.

1995 723 citations Stacia Kargman, Gary P. O’Neill et al. PubMed profile →
Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis

1990 622 citations Richard A. F. Dixon, Ronald E. Diehl et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip J. Vickers Canada	24	1.5k	1.3k	942	905	729	36	3.8k
John L. Humes United States	29	1.2k 0.8×	1.1k 0.8×	567 0.6×	473 0.5×	776 1.1×	63	3.7k
Elliott Sigal United States	27	1.0k 0.7×	1.6k 1.2×	650 0.7×	497 0.5×	1.0k 1.4×	54	4.8k
Yoshihito Nakatani Japan	28	1.9k 1.3×	1.9k 1.4×	487 0.5×	996 1.1×	521 0.7×	54	4.2k
Chieko Yokoyama Japan	35	1.9k 1.3×	2.8k 2.1×	690 0.7×	1.1k 1.2×	526 0.7×	80	6.1k
Hans‐Erik Claesson Sweden	34	726 0.5×	1.2k 0.9×	1.0k 1.1×	249 0.3×	1.0k 1.4×	109	3.6k
Curt Malmsten Sweden	27	1.2k 0.8×	983 0.7×	899 1.0×	297 0.3×	709 1.0×	40	3.4k
Daniel S. Straus United States	30	808 0.6×	2.9k 2.2×	576 0.6×	484 0.5×	787 1.1×	75	4.8k
Shuntaro Hara Japan	40	1.6k 1.1×	2.7k 2.0×	680 0.7×	1.2k 1.3×	722 1.0×	121	5.9k
Robert J. Bonney United States	29	745 0.5×	1.1k 0.9×	477 0.5×	239 0.3×	621 0.9×	56	3.2k
Ruth M. Kramer United States	34	531 0.4×	3.5k 2.7×	837 0.9×	630 0.7×	573 0.8×	54	5.4k

Countries citing papers authored by Philip J. Vickers

Since Specialization

Citations

This map shows the geographic impact of Philip J. Vickers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip J. Vickers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip J. Vickers more than expected).

Fields of papers citing papers by Philip J. Vickers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip J. Vickers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip J. Vickers. The network helps show where Philip J. Vickers may publish in the future.

Co-authorship network of co-authors of Philip J. Vickers

This figure shows the co-authorship network connecting the top 25 collaborators of Philip J. Vickers. A scholar is included among the top collaborators of Philip J. Vickers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip J. Vickers. Philip J. Vickers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vickers, Philip J., Carmela DeLuca, Elizabeth Wong, & Mark Abramovitz. (1997). The Effect of 5-Lipoxygenase-Activating Protein (Flap) on Substrate Utilization by 5-Lipoxygenase. Advances in experimental medicine and biology. 400A. 145–151. 2 indexed citations

Wong, Elizabeth, Carmela DeLuca, S. Charleson, et al.. (1997). Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. Inflammation Research. 46(2). 51–59. 34 indexed citations

Vickers, Philip J.. (1995). 5-Lipoxygenase-activating protein (FLAP). PubMed. 12(2-3). 185–194. 54 indexed citations

Mancini, Joseph A., Denis Riendeau, Jean‐Pierre Falgueyret, Philip J. Vickers, & Gary P. O’Neill. (1995). Arginine 120 of Prostaglandin G/H Synthase-1 Is Required for the Inhibition by Nonsteroidal Anti-inflammatory Drugs Containing a Carboxylic Acid Moiety. Journal of Biological Chemistry. 270(49). 29372–29377. 118 indexed citations

Kargman, Stacia, Gary P. O’Neill, Philip J. Vickers, et al.. (1995). Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.. PubMed. 55(12). 2556–9. 723 indexed citations breakdown →

Mancini, Joseph A., et al.. (1994). The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein. Life Sciences. 54(9). PL137–PL142. 13 indexed citations

Charleson, S., Jilly F. Evans, Serge Léger, et al.. (1994). Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein. European Journal of Pharmacology Molecular Pharmacology. 267(3). 275–280. 22 indexed citations

Mancini, Joseph A., Gary P. O’Neill, Christopher I. Bayly, & Philip J. Vickers. (1994). Mutation of serine‐516 in human prostaglandin G/H synthase‐2 to methionine or aspirin acetylation of this residue stimulates 15‐R‐HETE synthesis. FEBS Letters. 342(1). 33–37. 73 indexed citations

Woods, John, Jilly F. Evans, Diane Ethier, et al.. (1993). 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.. The Journal of Experimental Medicine. 178(6). 1935–1946. 341 indexed citations

10.

Mancini, Joseph A., Mark Abramovitz, Martha E. Cox, et al.. (1993). 5‐lipoxygenase‐activating protein is an arachidonate binding protein. FEBS Letters. 318(3). 277–281. 179 indexed citations

11.

Abramovitz, Mark, Elizabeth Wong, Martha E. Cox, et al.. (1993). 5‐Lipoxygenase‐activating protein stimulates the utilization of arachidonic acid by 5‐lipoxygenase. European Journal of Biochemistry. 215(1). 105–111. 173 indexed citations

12.

Mancini, Joseph A., Changlin Li, & Philip J. Vickers. (1993). 5-Lipoxygenase activity in the human pancreas.. PubMed. 8(3). 145–50. 8 indexed citations

13.

Tagari, Philip, Andreas Becker, Christine Brideau, et al.. (1993). Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591.. Journal of Pharmacology and Experimental Therapeutics. 265(1). 416–425. 12 indexed citations

14.

Mancini, Joseph A., Petpiboon Prasit, Marc G. Coppolino, et al.. (1992). 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.. Molecular Pharmacology. 41(2). 267–272. 31 indexed citations

15.

Vickers, Philip J., Gary P. O’Neill, Joseph A. Mancini, S. Charleson, & Mark Abramovitz. (1992). Cross-species comparison of 5-lipoxygenase-activating protein.. Molecular Pharmacology. 42(6). 1014–1019. 12 indexed citations

16.

Charleson, S., Petpiboon Prasit, Serge Léger, et al.. (1992). Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.. Molecular Pharmacology. 41(5). 873–879. 32 indexed citations

17.

Miller, Douglas K., John W. Gillard, Philip J. Vickers, et al.. (1990). Identification and isolation of a membrane protein necessary for leukotriene production. Nature. 343(6255). 278–281. 382 indexed citations

18.

Dixon, Richard A. F., Ronald E. Diehl, Evan E. Opas, et al.. (1990). Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 343(6255). 282–284. 622 indexed citations breakdown →

19.

Vickers, Philip J., et al.. (1988). A Multidrug-Resistant MCF-7 Human Breast Cancer Cell Line Which Exhibits Cross-Resistance to Antiestrogens and Hormone-Independent Tumor Growthin Vivo. Molecular Endocrinology. 2(10). 886–892. 137 indexed citations

20.

Vickers, Philip J., et al.. (1985). Activation of folylpolyglutamate synthetase by pteroic acid. Canadian Journal of Biochemistry and Cell Biology. 63(7). 777–779. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact